Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps

Advances in the therapy of atrial fibrillation (AF) have not come easily or quickly, despite the recognized need for significantly better antiarrhythmic agents for AF termination and prevention as well as for more user-friendly anticoagulants for the prevention of emboli in patients with AF. Rather,...

Descripción completa

Detalles Bibliográficos
Autor principal: Reiffel, James A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101191/
https://www.ncbi.nlm.nih.gov/pubmed/24821655
http://dx.doi.org/10.2174/1573403X1004140707121644
_version_ 1782480841791766528
author Reiffel, James A
author_facet Reiffel, James A
author_sort Reiffel, James A
collection PubMed
description Advances in the therapy of atrial fibrillation (AF) have not come easily or quickly, despite the recognized need for significantly better antiarrhythmic agents for AF termination and prevention as well as for more user-friendly anticoagulants for the prevention of emboli in patients with AF. Rather, the road has been only slowly progressive and bumpy. This manuscript will introduce the recent issues with dronedarone, the complex development story for vernakalant, and the appearance of the new oral anticoagulants. Each of these three considerations will then be explored in more depth by the invited experts for this “mini-Thematic issue” in Current Cardiology Reviews.
format Online
Article
Text
id pubmed-4101191
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-41011912015-11-01 Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps Reiffel, James A Curr Cardiol Rev Article Advances in the therapy of atrial fibrillation (AF) have not come easily or quickly, despite the recognized need for significantly better antiarrhythmic agents for AF termination and prevention as well as for more user-friendly anticoagulants for the prevention of emboli in patients with AF. Rather, the road has been only slowly progressive and bumpy. This manuscript will introduce the recent issues with dronedarone, the complex development story for vernakalant, and the appearance of the new oral anticoagulants. Each of these three considerations will then be explored in more depth by the invited experts for this “mini-Thematic issue” in Current Cardiology Reviews. Bentham Science Publishers 2014-11 2014-11 /pmc/articles/PMC4101191/ /pubmed/24821655 http://dx.doi.org/10.2174/1573403X1004140707121644 Text en © 2014 Bentham Science Publishers http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Reiffel, James A
Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
title Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
title_full Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
title_fullStr Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
title_full_unstemmed Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
title_short Editorial: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps
title_sort editorial: advances in the therapy of atrial fibrillation: incrementally progressive but not without missteps
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101191/
https://www.ncbi.nlm.nih.gov/pubmed/24821655
http://dx.doi.org/10.2174/1573403X1004140707121644
work_keys_str_mv AT reiffeljamesa editorialadvancesinthetherapyofatrialfibrillationincrementallyprogressivebutnotwithoutmissteps

Ejemplares similares